Jeonjinbio Co. Ltd
Jeonjinbio Co., Ltd. develops and produces natural bio-pesticides, alternative chemical products, and other biotechnology products. The company offers repellent for bird, boar, rodent, snake, and sea lice; and dress perfume, including Paris 16e, Paris 16e Bouquet, Bouquet Garni, and Bridcan, as well as mosquito repellent. It also provides laundry products. Jeonjin Bio Co., Ltd. was founded in 200… Read more
Jeonjinbio Co. Ltd (110020) - Net Assets
Latest net assets as of September 2025: ₩17.72 Billion KRW
Based on the latest financial reports, Jeonjinbio Co. Ltd (110020) has net assets worth ₩17.72 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩19.00 Billion) and total liabilities (₩1.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩17.72 Billion |
| % of Total Assets | 93.3% |
| Annual Growth Rate | 34.0% |
| 5-Year Change | 56.54% |
| 10-Year Change | N/A |
| Growth Volatility | 500.8 |
Jeonjinbio Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Jeonjinbio Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jeonjinbio Co. Ltd (2015–2024)
The table below shows the annual net assets of Jeonjinbio Co. Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.66 Billion | +183.96% |
| 2023-12-31 | ₩6.22 Billion | -34.59% |
| 2022-12-31 | ₩9.51 Billion | -11.93% |
| 2021-12-31 | ₩10.80 Billion | -4.31% |
| 2020-12-31 | ₩11.28 Billion | +289.25% |
| 2019-12-31 | ₩2.90 Billion | -25.89% |
| 2018-12-31 | ₩3.91 Billion | +1600.62% |
| 2017-12-31 | ₩229.96 Million | -89.92% |
| 2016-12-31 | ₩2.28 Billion | +80.07% |
| 2015-12-31 | ₩1.27 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jeonjinbio Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2202346986000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.53 Billion | 25.65% |
| Other Components | ₩41.22 Billion | 233.41% |
| Total Equity | ₩17.66 Billion | 100.00% |
Jeonjinbio Co. Ltd Competitors by Market Cap
The table below lists competitors of Jeonjinbio Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SaintMed Public Company Limited
BK:SMD
|
$11.69 Million |
|
Sun Peak Metals Corp
OTCQB:SUNPF
|
$11.69 Million |
|
Signal Advance Inc
PINK:SIGL
|
$11.70 Million |
|
Chuang's China Investments Limited
F:CUG
|
$11.70 Million |
|
Enwell Energy plc
PINK:RGPMF
|
$11.68 Million |
|
Seni Jaya Corporation Bhd
KLSE:9431
|
$11.68 Million |
|
FibroBiologics, Inc. Common Stock
NASDAQ:FBLG
|
$11.67 Million |
|
HOLALUZ-CLIDOM SA EO 003
F:4H2
|
$11.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jeonjinbio Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,219,660,920 to 17,661,431,640, a change of 11,441,770,720 (184.0%).
- Net income of 4,346,135,760 contributed positively to equity growth.
- Share repurchases of 997,732,300 reduced equity.
- New share issuances of 997,732,300 increased equity.
- Other factors increased equity by 7,095,634,960.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.35 Billion | +24.61% |
| Share Repurchases | ₩997.73 Million | -5.65% |
| Share Issuances | ₩997.73 Million | +5.65% |
| Other Changes | ₩7.10 Billion | +40.18% |
| Total Change | ₩- | 183.96% |
Book Value vs Market Value Analysis
This analysis compares Jeonjinbio Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.62x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩537.15 | ₩3020.00 | x |
| 2017-12-31 | ₩52.46 | ₩3020.00 | x |
| 2018-12-31 | ₩759.32 | ₩3020.00 | x |
| 2019-12-31 | ₩555.43 | ₩3020.00 | x |
| 2020-12-31 | ₩1867.27 | ₩3020.00 | x |
| 2021-12-31 | ₩1702.42 | ₩3020.00 | x |
| 2022-12-31 | ₩1390.09 | ₩3020.00 | x |
| 2023-12-31 | ₩834.20 | ₩3020.00 | x |
| 2024-12-31 | ₩1949.65 | ₩3020.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jeonjinbio Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.55%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.07x
- Recent ROE (24.61%) is above the historical average (-198.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -231.27% | -145.25% | 0.22x | 7.27x | ₩-3.06 Billion |
| 2016 | -134.69% | -63.92% | 0.82x | 2.55x | ₩-3.30 Billion |
| 2017 | -1322.38% | -96.97% | 0.77x | 17.64x | ₩-3.06 Billion |
| 2018 | -86.91% | -245.50% | 0.19x | 1.82x | ₩-3.79 Billion |
| 2019 | -50.46% | -37.03% | 0.62x | 2.21x | ₩-1.75 Billion |
| 2020 | -30.30% | -88.40% | 0.21x | 1.66x | ₩-4.55 Billion |
| 2021 | -19.53% | -65.59% | 0.13x | 2.30x | ₩-3.19 Billion |
| 2022 | -32.74% | -39.94% | 0.44x | 1.88x | ₩-4.06 Billion |
| 2023 | -103.54% | -41.07% | 0.89x | 2.85x | ₩-7.06 Billion |
| 2024 | 24.61% | 22.55% | 1.02x | 1.07x | ₩2.58 Billion |
Industry Comparison
This section compares Jeonjinbio Co. Ltd's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $729,340,395,312
- Average return on equity (ROE) among peers: 5.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jeonjinbio Co. Ltd (110020) | ₩17.72 Billion | -231.27% | 0.07x | $11.69 Million |
| DL Holdings CO. LTD. (000210) | $4.53 Trillion | 19.10% | 0.84x | $381.57 Million |
| Norooholdings (000320) | $402.45 Billion | 6.30% | 1.12x | $45.80 Million |
| Noroo Holdings Co Ltd (000325) | $583.54 Billion | 0.27% | 0.81x | $60.77 Million |
| Samhwa Paint (000390) | $299.72 Billion | 1.87% | 0.96x | $86.24 Million |
| Kangnam Jevisco Co Ltd (000860) | $366.15 Billion | 10.97% | 0.26x | $58.42 Million |
| Paik Kwang Ind (001340) | $204.57 Billion | 3.85% | 1.06x | $113.44 Million |
| Bo Lak (002760) | $43.76 Billion | 2.53% | 0.22x | $30.02 Million |
| Songwon Industrial (004430) | $543.25 Billion | 13.30% | 1.05x | $79.87 Million |
| Cho Kwang Pain (004910) | $172.73 Billion | -1.34% | 0.81x | $17.90 Million |
| Cosmoam&T (005070) | $147.00 Billion | -3.99% | 0.78x | $305.37 Million |